Last Updated on January 19, 2025
A Texas father who has been in a years-long battle to stop his ex-wife from allowing their pre-teen son from “gender-affirming care” has reportedly been given assurances by top-level insiders in the Trump administration that policies will be instituted to save his son from chemical castration.
Jeff Young announced on X last November that he “lost all parental rights” over his twin sons after Los Angeles Superior Court Judge Mark Juhas granted his estranged pediatrician ex-wife Anne Georgulas the authority to “castrate” his 12-year-old son James. James identifies as a girl named “Luna.”
“Let my story be a cautionary one for young men. Fathers have no rights to their children,” Young noted at the time of Judge Juhas’ ruling.
The U.S. Department of Health claims chemical castration, which involves the use of puberty-blocking drugs to stop sex hormone production, claims the practice is reversible. Yet the long-term side effects of so-called chemical castration remain a mystery. Studies show that those undergoing the procedure suffer from bone density loss.
In 2018, the battle between Younger and his ex-wife Georgulas made headlines after she sought a restraining order against Younger to bar him from entering their sons’ school. As the Washington Post reported, Georgulas also sought to block Younger from disclosing to other parents that “the gender of Luna is different than a girl named Luna.”
Fighting for his son’s health and his parental rights for nearly seven years, Young claims he is now coordinating with insiders of the incoming Trump administration who are slated to about “explosive” plans to “save” his underaged son and other children in Democrat-run cities from being able to legally mutilate their genitals in the name of “gender affirmation.”
“I am in contact with top-level insiders in the Trump Administration. Expect explosive reveals in the next few weeks about saving my son from chemical castration,” Young wrote in an article published on the X platform on Thursday. “The problem is NOT fixed. California, Minnesota, Oregon, and Washington are castrating kids without parental consent. We need a federal investigation.”
In addition to persuading a judge to sever Younger’s parental rights, Georgulas is suing Young for attorney fees to the tune of approximately $100,000.
“Judge Juhas gave all the parental rights to my ex-wife to castrate my son,” the crusading father wrote. “I have begun the appeal process. It’s expensive. Appellate lawyers charge $700/hr. If you can, donate here. My ex-wife seeks sanctions and attorney fees of $61,000.”
Younger underscored the measures he is taking to reestablish parental rights nationwide surrounding allegedly transgender children and outlaw now-government-sanctioned body dysphoria of minors.
“I am generating enormous public pressure,” Younger explains in a section of the article titled “Current Activities.”
“I am initiating a proposition process to outlaw these barbaric transgender practices in California. We intend to bypass the legislature and go directly to the people,” he wrote. “I work with activists in Florida, South Carolina, North Carolina, North Dakota, and Delaware. We’re going to outlaw transgender sexual abuse of kids everywhere. I am launching several media initiatives to support all of this.
“Recall election for the California judge who did this to my son. It’s expensive to remove judges. Help the recall effort.”
While judges grant custody to parents who have advocated for their kids to undergo genital mutilation, and “gender-affirming” treatments and obtain “transition” related medications, the number of children who obtain these sorts of treatments and procedures is extremely rare in the United States.
A study published by JAMA Pediatrics on Monday found less than 0.1 percent of adolescents with private insurance in the United States identify as “transgender” or “gender-diverse” and are prescribed gender-transitioning hormones, cross-sex hormone medications or puberty blockers.
Using analysis of the Census Bureau to analyze the number of private insurance claims for more than 5.1 million young patients ages 8 to 17 from 2018 to 2022, the study found no transgender patients under 12 were prescribed gender-affirming hormones. Private insurers covered 65% of the country as of 2023.
